Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tramadol + pethidine is a combination of two synthetic opioid analgesics, each with distinct mechanisms of action, used for the management of moderate to severe pain. Tramadol acts as a centrally acting opioid agonist and also inhibits the reuptake of serotonin and norepinephrine, providing both opioid and monoaminergic analgesic effects[1][5][6]. Pethidine (also known as meperidine) is a strong opioid that primarily acts as an agonist at the μ-opioid receptor to inhibit pain signaling in the central nervous system[8]. While both drugs are effective for acute pain relief, their use together is not standard practice due to overlapping side effect profiles and increased risk of adverse events such as respiratory depression, sedation, constipation, nausea, vomiting, and potential for dependence or addiction. Both agents are prescription-only medications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tramadol + pethidine.